×
About 7,045 results

ALLMedicine™ Hemolytic Anemia Center

Research & Reviews  2,118 results

Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma
https://www.mdedge.com/fedprac/avaho/article/255829/multiple-myeloma/simultaneous-cases-carfilzomib-induced-thrombotic
Nathaniel J. Myall, MD, Samantha X. Wang, MD et. al.

Jun 28th, 2022 - As a class of drugs, proteasome inhibitors are known to rarely cause drug-induced thrombotic microangiopathy (DITMA). In particular, carfilzomib is a second-generation, irreversible proteasome inhibitor approved for the treatment of relapsed, refr.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
https://clinicaltrials.gov/ct2/show/NCT04691570

Jun 24th, 2022 - After being informed of study details and potential risks, all participants who provide written informed consent will undergo an up to 6-week screening period to determine eligibility. Participants who meet the eligibility criteria will receive tw...

Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease
https://clinicaltrials.gov/ct2/show/NCT03685721

Jun 24th, 2022 - Polymerization of deoxy-sickle-hemoglobin (deoxy-HbS), the root cause of sickle cell disease (SCD) is influenced by a few factors, a key factor is 2,3-diphosphoglycerate (2,3-DPG) concentration in the red blood cells. 2,3-DPG is an allosteric effe...

PARADIGM: Amplatzer Valvular Plug for PVL Closure
https://clinicaltrials.gov/ct2/show/NCT04489823

Jun 24th, 2022 - PARADIGM is a prospective, international, multi-center, single arm study to demonstrate the safety and effectiveness of the AVP III for percutaneous, transcatheter closure of PVLs occurring after aortic or mitral valve replacement with a surgicall...

Mechanisms Accounting for Unexplained Anemia in the Elderly
https://clinicaltrials.gov/ct2/show/NCT01572506

Jun 24th, 2022 - Anemia occurs commonly and is associated with adverse outcomes in the elderly. In approximately one third of anemia cases in patients over the age of 65 years, the cause of anemia is not readily apparent (unexplained anemia or UA). Of the various ...

see more →

Guidelines  3 results

Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344868
American Journal of Hematology; Bianchi P, Fermo E et. al.

Oct 26th, 2018 - Pyruvate kinase deficiency (PKD) is the most common enzyme defect of glycolysis and an important cause of hereditary, nonspherocytic hemolytic anemia. The disease has a worldwide geographical distribution but there are no verified data regarding i...

Clinical guides for atypical hemolytic uremic syndrome in Japan.
https://doi.org/10.1007/s10157-016-1276-6
Clinical and Experimental Nephrology; Kato H, Nangaku M et. al.

Jul 17th, 2016 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely ...

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase t...
https://doi.org/10.1038/clpt.2014.97
Clinical Pharmacology and Therapeutics; Relling MV, McDonagh EM et. al.

May 3rd, 2014 - Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with development of acute hemolytic anemia (AHA) induced by a number of drugs. We provide guidance as to which G6PD genotypes are associated with G6PD deficiency in males and female...

see more →

Drugs  407 results see all →

Clinicaltrials.gov  126 results

PARADIGM: Amplatzer Valvular Plug for PVL Closure
https://clinicaltrials.gov/ct2/show/NCT04489823

Jun 24th, 2022 - PARADIGM is a prospective, international, multi-center, single arm study to demonstrate the safety and effectiveness of the AVP III for percutaneous, transcatheter closure of PVLs occurring after aortic or mitral valve replacement with a surgicall...

Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease
https://clinicaltrials.gov/ct2/show/NCT03685721

Jun 24th, 2022 - Polymerization of deoxy-sickle-hemoglobin (deoxy-HbS), the root cause of sickle cell disease (SCD) is influenced by a few factors, a key factor is 2,3-diphosphoglycerate (2,3-DPG) concentration in the red blood cells. 2,3-DPG is an allosteric effe...

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
https://clinicaltrials.gov/ct2/show/NCT04691570

Jun 24th, 2022 - After being informed of study details and potential risks, all participants who provide written informed consent will undergo an up to 6-week screening period to determine eligibility. Participants who meet the eligibility criteria will receive tw...

Mechanisms Accounting for Unexplained Anemia in the Elderly
https://clinicaltrials.gov/ct2/show/NCT01572506

Jun 24th, 2022 - Anemia occurs commonly and is associated with adverse outcomes in the elderly. In approximately one third of anemia cases in patients over the age of 65 years, the cause of anemia is not readily apparent (unexplained anemia or UA). Of the various ...

The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia
https://clinicaltrials.gov/ct2/show/NCT05004259

Jun 21st, 2022 - Autoimmune Hemolytic Anemia (AIHA) is a hematologic disorder in which the red blood cells are targeted and destroyed by autoantibodies produced by the immune system, specifically B-cells and plasma cells. It can be either idiopathic, or secondary ...

see more →

News  162 results

Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma
https://www.mdedge.com/fedprac/avaho/article/255829/multiple-myeloma/simultaneous-cases-carfilzomib-induced-thrombotic
Nathaniel J. Myall, MD, Samantha X. Wang, MD et. al.

Jun 28th, 2022 - As a class of drugs, proteasome inhibitors are known to rarely cause drug-induced thrombotic microangiopathy (DITMA). In particular, carfilzomib is a second-generation, irreversible proteasome inhibitor approved for the treatment of relapsed, refr.

Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC
https://www.onclive.com/view/sotorasib-shows-impressive-2-year-os-rate-in-kras-g12c-nsclc

May 2nd, 2022 - Sotorasib (Lumakras) demonstrated an overall survival (OS) rate of 32.5% (95% CI, 25.0%-40.2%) at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC), according to longer follow-up data from the phase 1/2 CodeBreaK 100 tri...

Higher Dose Primaquine Promising for Malaria Relapse Prevention
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/97967

Mar 31st, 2022 - A higher dose of a primaquine-based regimen was more effective at preventing relapses of Plasmodium vivax malaria than the currently recommended regimen, a randomized trial found. More patients randomized to receive a higher dose of the antiparasi...

FDA Approves First Drug for Rare Inherited Anemia
https://www.medscape.com/viewarticle/968795

Feb 18th, 2022 - A new drug that is both the first in its class and the first disease-modifying agent for hemolytic anemia in adults with pyruvate kinase (PK) deficiency has been approved by the US Food and Drug Administration (FDA). The new drug, mitapivat (Pyruk...

FDA Approves First Drug for Cold Agglutinin Disease
https://www.medscape.com/viewarticle/967966

Feb 7th, 2022 - A new drug has become the first and only treatment for people with cold agglutinin disease (CAD) that is approved by the US Food and Drug Administration (FDA). CAD is a rare autoimmune hemolytic anemia, affecting about 5000 people in the United St...

see more →

Patient Education  2 results see all →